James Sullivan

James Sullivan

Chief Scientific OfficeratenGene Therapeutics· In proxies 2022–2023

Pay in FY2023+104% from the year before

James Sullivan was paid $896.2K in FY2023 (Oct), up 104%.

PayNo stock prices for these years
Pay is from the Summary Compensation Table of each enGene Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. enGene TherapeuticsPublic company · 4 yr
    • Chief Scientific Officer2022 – Present · 4 yrStock in role -92%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?